Global guideline · conditional recommendations
  • WHO’s recommendations are conditional and concern long-term care.
  • Availability depends on more than regulatory approval.
  • Global guidance does not establish UK prescribing eligibility.

What the guideline recommends

On 1 December 2025, the World Health Organization issued its first guideline on GLP-1 therapies for treating adult obesity. It conditionally supported long-term use in adults, excluding pregnant women, and conditionally supported offering intensive behavioural interventions alongside treatment. The guideline specifically addresses liraglutide, semaglutide and tirzepatide.

Conditional does not mean that the evidence shows no benefit. WHO cited remaining questions about long-term outcomes, maintenance and discontinuation, as well as costs, health-system readiness and equity. These considerations affect how a treatment recommendation can be put into practice.

Access is part of the clinical story

WHO’s accompanying questions and answers explains that availability depends on national registration, production, cost and supply. Access is uneven between countries and is lower in many low- and middle-income settings. A medicine’s existence therefore does not mean that everyone who might benefit can obtain consistent care.

This creates a practical distinction between starting treatment and being able to sustain it. Our interpretation is that a meaningful comparison should consider follow-up, continuity, affordability and support alongside the medicine itself. A convenient purchasing route cannot answer all of those questions.

The guidance frames obesity as a chronic condition requiring comprehensive care. WHO also says medicines should sit alongside healthy eating and physical activity. That is a statement about the scope of care, rather than a reason to reduce obesity to personal willpower.

What it means for someone in the UK

A global recommendation is not a UK marketing authorisation, a NICE funding decision or confirmation of eligibility at a local service. It provides an international framework that countries must translate into their own systems.

For an individual, the useful discussion is about an agreed long-term plan: the health outcomes being pursued, how treatment will be reviewed, what support is available and what happens if treatment must change. WHO’s guidance helps explain why those questions belong beside any discussion of average weight loss.

← More research & news
Follow the evidence

Sources & further reading

These links support the information above; they do not imply endorsement of this website.

  1. WHO: first GLP-1 obesity guideline announcement, 1 December 2025
  2. WHO: questions and answers on obesity and GLP-1 therapies, 2 December 2025
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →